JCC: Curcubin in turmeric can improve the symptoms of Crohn's disease

Crohn's disease (CD) and ulcerative colitis (UC) are the two main manifestations of chronic inflammatory bowel disease (IBD).
, CD is characterized by the formation of an unsethical but full layer of inflammatory granuloma anywhere in the digestive tract.
causes of CDs are not yet fully known and there is no cure.
therefore, the purpose of current drug therapy is to control inflammation or prevent its deterioration.
drugs include anti-tumor necrotic factor (TNF)-α, lecytolein (IL)-23 and IL-17 antibodies.
, many patients require surgical intervention after failing to achieve remission through biotherapy.
Curcubin is a natural substance that has been used as a food additive for hundreds of years and is a yellow turmeric powder extracted from turmeric plants that strongly inhibits the expression of nuclear factors -NF-B) and downstream inflammatory cytokines such as TNF-α.
However, its absorption in the intestines is very slow, and the newly synthesized curcumin derivative Theracurmin has a 27-fold higher absorption ratio than conventional curcumin powders, so this study aims to explore the efficacy and safety of Theracurmin's treatment of CD patients.
in a randomized double-blind study conducted at five independent medical centers in Japan, researchers randomized all patients with mild to moderate Crohn's disease into the Tharacurmin group (360 mg/day, n s 20) or the placebo group (n s 10) for 12 weeks to assess the efficacy of the drug by evaluating clinical and endoscopic remission, healing of lesions, and blood levels of inflammatory markers.
in the Theracurmin group, there was a significant decrease in clinical disease activity at 12 weeks compared to week 0 (P= 0 0.005).
in the intentional therapy analysis, the clinical remission rates at weeks 4, 8 and 12 were 35%, 40% and 40%, respectively, significantly higher than in the placebo group (both 0%;p s 0.033, p s 0 .020 and p s 0 .020).
addition, Theracurmin was significantly better at reducing the severity of Crohn's disease in endoscopes than in the control group (P s 0 0.032).
week 8, the healing of injuries in the Theracurmin group was significantly higher (p s 0.017).
no serious adverse events were observed in neither group throughout the study.
this study confirms that Theracurmin has significant clinical effects for reducing inflammation and is highly safe for treating mild to moderate Crohn's disease.
。